Ireland
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies. Headquartered in Dublin, Ireland, the company operates in the United States, Europe, and internationally.
Key Products
- Xywav – Treats cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH).
- Xyrem – Addresses cataplexy or EDS in narcolepsy patients.
- Epidiolex – Used for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC).
- Rylaze & Enrylaze – Treat acute lymphoblastic leukemia and lymphoblastic lymphoma.
- Zepzelca – Targets metastatic small cell lung cancer post-platinum-based chemotherapy.
- Ziihera – Addresses HER2-positive biliary tract cancers.
- Defitelio – Used for severe veno-occlusive disease.
- Vyxeos – Treats newly-diagnosed therapy-related acute myeloid leukemia.
Pipeline Highlights
- Zanidatamab – Phase 3 trial for HER2-expressing gastroesophageal adenocarcinoma (GEA).
- Epidiolex – Phase 3 trial for LGS, DS, and TSC.
- Suvecaltamide – Phase 2 trial for Parkinson's disease tremor.
- JZP815 – Phase 1 pan-RAF kinase inhibitor targeting MAP kinase.
- JZP898 – Phase 1 conditionally activated interferon alpha molecule.
- JZP441 – Phase 1 trial for narcolepsy, IH, and sleep disorders.
- JZP324 – Phase 1 extended-release low sodium oxybate for sleep disorders.
- JZP150 – Investigational treatment for post-traumatic stress disorder.
Strategic Collaborations
Jazz Pharmaceuticals has licensing and collaboration agreements with:
- Redx Pharma plc
- Autifony Therapeutics Limited
- Zymeworks Inc.
- Sumitomo Pharma Co., Ltd.
- Werewolf Therapeutics, Inc.
Founded in 2003, Jazz Pharmaceuticals continues to advance its mission of delivering life-changing therapies to patients worldwide.
